Sanofi India Q3'26: Interim Dividend ₹75/share, Profit Before Tax Rises 22% to ₹158 Crore
Sanofi India reported Q3'26 results with total net sales up 4%. Profit before tax increased 22% to ₹158 crore. The company declared an interim dividend of ₹75 per share, with November 5, 2026, set as the record date. The diabetes portfolio grew 9%.
The declaration of an interim dividend and strong financial results are material events for shareholders, impacting investment decisions.
The company reported a 22% increase in profit before tax and declared a significant interim dividend, indicating positive financial performance.
Sanofi India Limited announced its financial results for the quarter and nine months ended September 30, 2026. The company's Board of Directors, in a meeting held on October 29, 2026, approved the unaudited financial results.
For the quarter ended September 30, 2026, Sanofi India reported domestic net sales growth of 2% and total net sales growth of 4% compared to the third quarter of 2025. The Insulin portfolio showed strong performance with 9% growth, maintaining a 55% market share in the Diabetes Injectable segment. Public sector business saw a significant surge of 85% due to new accounts. Export sales also delivered good double-digit growth.
Profits before tax and exceptional items rose by 22% to ₹158 crore (1580 million) from ₹130 crore (1300 million) in the third quarter of 2025. Profit before tax as a percentage of net sales improved to 34% from 29% in the prior year's comparable quarter. This improvement was attributed to a favorable product mix, a one-off reversal of provisions, and disciplined cost management, with operating expenses declining by 8%.
The Board also declared an interim dividend of ₹75 per equity share of ₹10 face value for the financial year 2026. The company has fixed Thursday, November 5, 2026, as the record date for the payment of this interim dividend.
What to do with a filing like this
Sanofi India Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sanofi India Limited. Read the original for the full detail.